Pallas Capital Advisors LLC Raises Holdings in IQVIA Holdings Inc. $IQV

Pallas Capital Advisors LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 113.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,000 shares of the medical research company’s stock after buying an additional 6,371 shares during the quarter. Pallas Capital Advisors LLC’s holdings in IQVIA were worth $1,891,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. American National Bank & Trust purchased a new stake in shares of IQVIA in the first quarter worth about $26,000. Clal Insurance Enterprises Holdings Ltd boosted its position in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after purchasing an additional 131 shares in the last quarter. Golden State Wealth Management LLC boosted its position in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC purchased a new position in IQVIA during the first quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. boosted its position in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Activity

In other news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on IQV. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Citigroup reissued a “neutral” rating on shares of IQVIA in a report on Thursday, May 22nd. Evercore ISI increased their target price on IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a report on Wednesday, July 9th. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and increased their target price for the company from $195.00 to $225.00 in a report on Tuesday, September 9th. Finally, Cowen reaffirmed a “buy” rating on shares of IQVIA in a report on Wednesday, July 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $229.64.

IQVIA Stock Down 0.0%

Shares of IQVIA stock opened at $186.79 on Thursday. The company has a fifty day moving average price of $183.81 and a 200 day moving average price of $167.38. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $248.03. The stock has a market cap of $31.75 billion, a price-to-earnings ratio of 27.03, a price-to-earnings-growth ratio of 2.05 and a beta of 1.32.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same period in the prior year, the company posted $2.64 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.